Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk

被引：11
|
作者：
Arnott, Clare [1 ,2 ,3 ]
Fletcher, Robert A. [1 ]
Neal, Bruce [1 ,4 ]
机构：
[1] Univ New South Wales, George Inst Global Hlth, Level 5,1 King St, Sydney, NSW 2042, Australia
[2] Royal Prince Alfred Hosp, Dept Cardiol, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Imperial Coll London, Dept Epidemiol & Biostat, London, England
来源：
HEART FAILURE CLINICS | 2022年 / 18卷 / 04期
关键词：
SGLT2; inhibitors; Meta-analysis; Amputation; Fracture; TYPE-2; CANAGLIFLOZIN;
D O I：
10.1016/j.hfc.2022.03.008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：645 / 654
页数：10
相关论文
共 50 条
  • [21] Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials
    Cheng, L.
    Li, Y-Y
    Hu, W.
    Bai, F.
    Hao, H-R
    Yu, W-N
    Mao, X-M
    DIABETES & METABOLISM, 2019, 45 (05) : 436 - 445
  • [22] Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
    Salah, Husam M.
    Fudim, Marat
    HEART FAILURE CLINICS, 2022, 18 (04) : 625 - 634
  • [23] Lipid effects of sodium-glucose cotransporter 2 inhibitors
    Lazarte, Julieta
    Kanagalingam, Tharsan
    Hegele, Robert A.
    CURRENT OPINION IN LIPIDOLOGY, 2021, 32 (03) : 183 - 190
  • [24] Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
    Salah, Husam M.
    Verma, Subodh
    Santos-Gallego, Carlos G.
    Bhatt, Ankeet S.
    Vaduganathan, Muthiah
    Khan, Muhammad Shahzeb
    Lopes, Renato D.
    Al'Aref, Subhi J.
    McGuire, Darren K.
    Fudim, Marat
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2022, 15 (05) : 944 - 956
  • [25] Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation
    Werkman, Nikki C. C.
    Nielen, Johannes T. H.
    van den Bergh, Joop P. W.
    Ejskjaer, Niels
    Roikjer, Johan
    Schaper, Nicolaas C.
    Rossi, Bernardette
    Klungel, Olaf
    Vestergaard, Peter
    de Vries, Frank
    Driessen, Johanna H. M.
    CURRENT DRUG SAFETY, 2021, 16 (01) : 62 - 72
  • [26] Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
    Jasleen, Bains
    Vishal, Gupta K.
    Sameera, Malepati
    Fahad, Molla
    Brendan, O'Brien
    Deion, Santander
    Pemminati, Sudhakar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [27] The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?
    Sarafidis, Pantelis A.
    Ortiz, Alberto
    CLINICAL KIDNEY JOURNAL, 2020, 13 (01) : 24 - 26
  • [28] Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
    Ye, Yangli
    Zhao, Chenhe
    Liang, Jing
    Yang, Yinqiu
    Yu, Mingxiang
    Qu, Xinhua
    FRONTIERS IN PHARMACOLOGY, 2019, 9
  • [29] Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers
    Somagutta, Manoj R.
    Agadi, Kuchalambal
    Hange, Namrata
    Jain, Molly S.
    Batti, Erkan
    Emuze, Bernard O.
    Amos-Arowoshegbe, Elizabeth O.
    Popescu, Sorin
    Hanan, Saad
    Kumar, Varadha Retna
    Pormento, Kezia
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (03)
  • [30] Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure
    Docherty, Kieran F.
    Petrie, Mark C.
    HEART, 2022, 108 (04) : 312 - 320
12345